<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39220656</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>06</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2328-8957</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Open forum infectious diseases</Title><ISOAbbreviation>Open Forum Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Postacute Sequelae of COVID (PASC or Long COVID): An Evidenced-Based Approach.</ArticleTitle><Pagination><StartPage>ofae462</StartPage><MedlinePgn>ofae462</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">ofae462</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/ofid/ofae462</ELocationID><Abstract><AbstractText>While the acute manifestations of infectious diseases are well known, in some individuals, symptoms can either persist or appear after the acute period. Postviral fatigue syndromes are recognized with other viral infections and are described after coronavirus disease 2019 (COVID-19). We have a growing number of individuals with symptoms that persist for weeks, months, and years. Here, we share the evidence regarding the abnormalities associated with postacute sequelae of COVID-19 (PASC) and therapeutics. We describe physiological and biochemical abnormalities seen in individuals reporting PASC. We describe the several evidence-based interventions to offer patients. It is expected that this growing understanding of the mechanisms driving PASC and the benefits seen with certain therapeutics may not only lead to better outcomes for those with PASC but may also have the potential for understanding and treating other postinfectious sequelae.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Griffin</LastName><ForeName>Daniel O</ForeName><Initials>DO</Initials><Identifier Source="ORCID">0000-0001-5853-6906</Identifier><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Medicine, Columbia University, College of Physicians and Surgeons, New York, New York, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Open Forum Infect Dis</MedlineTA><NlmUniqueID>101637045</NlmUniqueID><ISSNLinking>2328-8957</ISSNLinking></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Open Forum Infect Dis. 2024 Sep 05;11(9):ofae509. doi: 10.1093/ofid/ofae509</RefSource><PMID Version="1">39238844</PMID></CommentsCorrections></CommentsCorrectionsList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">PASC</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">postacute sequelae of COVID</Keyword></KeywordList><CoiStatement>Potential conflicts of interest. The author is a director of Parasites without Borders and MicrobeTV. The author has consulted for Pfizer and Shionogi.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>2</Day><Hour>8</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>2</Day><Hour>8</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>2</Day><Hour>5</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39220656</ArticleId><ArticleId IdType="pmc">PMC11363684</ArticleId><ArticleId IdType="doi">10.1093/ofid/ofae462</ArticleId><ArticleId IdType="pii">ofae462</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Guan &#xa0;WJ, Ni &#xa0;Z-Y, Hu &#xa0;Y, et al. &#xa0;Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med &#xa0;2020; 382:1708&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7092819</ArticleId><ArticleId IdType="pubmed">32109013</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta &#xa0;P, McAuley &#xa0;DF, Brown &#xa0;M, et al. &#xa0;COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet &#xa0;2020; 395:1033&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7270045</ArticleId><ArticleId IdType="pubmed">32192578</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffin &#xa0;DO, Brennan-Rieder &#xa0;D, Ngo &#xa0;B, et al. &#xa0;The importance of understanding the stages of COVID-19 in treatment and trials. AIDS Rev &#xa0;2021; 23:40&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">33556957</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunmire &#xa0;SK, Verghese &#xa0;PS, Balfour &#xa0;HH &#xa0;Jr. Primary Epstein-Barr virus infection. J Clin Virol &#xa0;2018; 102:84&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">29525635</ArticleId></ArticleIdList></Reference><Reference><Citation>Stefano &#xa0;GB. Historical insight into infections and disorders associated with neurological and psychiatric sequelae similar to long COVID. Med Sci Monit &#xa0;2021; 27:e931447.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7924007</ArticleId><ArticleId IdType="pubmed">33633106</ArticleId></ArticleIdList></Reference><Reference><Citation>Stawicki &#xa0;SP, Sharpe &#xa0;RP, Galwankar &#xa0;SC, et al. &#xa0;Reflections on the Ebola public health emergency of international concern, part 1: post-Ebola syndrome: the silent outbreak. J Glob Infect Dis &#xa0;2017; 9:41&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5452549</ArticleId><ArticleId IdType="pubmed">28584453</ArticleId></ArticleIdList></Reference><Reference><Citation>Bond &#xa0;NG, Grant &#xa0;DS, Himmelfarb &#xa0;ST, et al. &#xa0;Post-Ebola syndrome presents with multiple overlapping symptom clusters: evidence from an ongoing cohort study in eastern Sierra Leone. Clin Infect Dis &#xa0;2021; 73:1046&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8442780</ArticleId><ArticleId IdType="pubmed">33822010</ArticleId></ArticleIdList></Reference><Reference><Citation>Punsoni &#xa0;M, Lakis &#xa0;NS, Mellion &#xa0;M, de la Monte &#xa0;SM. Post-polio syndrome revisited. Neurol Int &#xa0;2023; 15:569&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10123742</ArticleId><ArticleId IdType="pubmed">37092507</ArticleId></ArticleIdList></Reference><Reference><Citation>Choutka &#xa0;J, Jansari &#xa0;V, Hornig &#xa0;M, Iwasaki &#xa0;A. Unexplained post-acute infection syndromes. Nat Med &#xa0;2022; 28:911&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">35585196</ArticleId></ArticleIdList></Reference><Reference><Citation>Choutka &#xa0;J, Jansari &#xa0;V, Hornig &#xa0;M, Iwasaki &#xa0;A. Author correction: unexplained post-acute infection syndromes. Nat Med &#xa0;2022; 28:1723.</Citation><ArticleIdList><ArticleId IdType="pubmed">35859204</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie &#xa0;Y, Bowe &#xa0;B, Al-Aly &#xa0;Z. Burdens of post-acute sequelae of COVID-19 by severity of acute infection, demographics and health status. Nat Commun &#xa0;2021; 12:6571.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8589966</ArticleId><ArticleId IdType="pubmed">34772922</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly &#xa0;Z, Xie &#xa0;Y, Bowe &#xa0;B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature &#xa0;2021; 594:259&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">33887749</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis &#xa0;HE, McCorkell &#xa0;L, Vogel &#xa0;JM, Topol &#xa0;EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol &#xa0;2023; 21:133&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein &#xa0;J, Wood &#xa0;J, Jaycox &#xa0;JR, et al. &#xa0;Distinguishing features of long COVID identified through immune profiling. Nature &#xa0;2023; 623:139&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10620090</ArticleId><ArticleId IdType="pubmed">37748514</ArticleId></ArticleIdList></Reference><Reference><Citation>Funk &#xa0;AL, Kuppermann &#xa0;N, Florin &#xa0;TA, et al. &#xa0;Post-COVID-19 conditions among children 90 days after SARS-CoV-2 infection. JAMA Netw Open &#xa0;2022; 5:e2223253.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9308058</ArticleId><ArticleId IdType="pubmed">35867061</ArticleId></ArticleIdList></Reference><Reference><Citation>Kompaniyets &#xa0;L, Bull-Otterson &#xa0;L, Boehmer &#xa0;TK, et al. &#xa0;Post-COVID-19 symptoms and conditions among children and adolescents&#x2014;United States, March 1, 2020-January 31, 2022. MMWR Morb Mortal Wkly Rep &#xa0;2022; 71:993&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9368731</ArticleId><ArticleId IdType="pubmed">35925799</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao &#xa0;S, Lee &#xa0;GM, Razzaghi &#xa0;H, et al. &#xa0;Clinical features and burden of post-acute sequelae of SARS-CoV-2 infection in children and adolescents: an exploratory EHR-based cohort study from the RECOVER program. JAMA Pediatr &#xa0;2022; 176:1000&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9396470</ArticleId><ArticleId IdType="pubmed">35994282</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian &#xa0;A, Nirantharakumar &#xa0;K, Hughes &#xa0;S, et al. &#xa0;Symptoms and risk factors for long COVID in non-hospitalized adults. Nat Med &#xa0;2022; 28:1706&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9388369</ArticleId><ArticleId IdType="pubmed">35879616</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenhalgh &#xa0;T, Sivan &#xa0;M, Delaney &#xa0;B, Evans &#xa0;R, Milne &#xa0;R. Long COVID&#x2014;an update for primary care. BMJ &#xa0;2022; 378:e072117.</Citation><ArticleIdList><ArticleId IdType="pubmed">36137612</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffin &#xa0;DO, Jensen &#xa0;A, Khan &#xa0;M, et al. &#xa0;Pulmonary embolism and increased levels of D-dimer in patients with coronavirus disease. Emerg Infect Dis &#xa0;2020; 26:1941&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7392455</ArticleId><ArticleId IdType="pubmed">32348233</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffin &#xa0;DO, Jensen &#xa0;A, Khan &#xa0;M, et al. &#xa0;Cytokine storm of a different flavor: the different cytokine signature of SARS-CoV2 the cause of COVID-19 from the original SARS outbreak. J Glob Antimicrob Resist &#xa0;2020; 24:90&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7682938</ArticleId><ArticleId IdType="pubmed">33242672</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffin &#xa0;DO, Jensen &#xa0;A, Khan &#xa0;M, et al. &#xa0;Arterial thromboembolic complications in COVID-19 in low-risk patients despite prophylaxis. Br J Haematol &#xa0;2020; 190:e11&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7267572</ArticleId><ArticleId IdType="pubmed">32374029</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffin &#xa0;DO. COVID-19: using the right tools at the right time. Med Res Arch &#xa0;2022; 10.</Citation></Reference><Reference><Citation>Callard &#xa0;F, Perego &#xa0;E. How and why patients made long COVID. Soc Sci Med &#xa0;2021; 268:113426.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7539940</ArticleId><ArticleId IdType="pubmed">33199035</ArticleId></ArticleIdList></Reference><Reference><Citation>Alwan &#xa0;NA, Johnson &#xa0;L. Defining long COVID: going back to the start. Med &#xa0;2021; 2:501&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7992371</ArticleId><ArticleId IdType="pubmed">33786465</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfel &#xa0;R, Corman &#xa0;VM, Guggemos &#xa0;W, et al. &#xa0;Virological assessment of hospitalized patients with COVID-2019. Nature &#xa0;2020; 581:465&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">32235945</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfel &#xa0;R, Corman &#xa0;VM, Guggemos &#xa0;W, et al. &#xa0;Author correction: virological assessment of hospitalized patients with COVID-2019. Nature &#xa0;2020; 588:E35.</Citation><ArticleIdList><ArticleId IdType="pubmed">33303961</ArticleId></ArticleIdList></Reference><Reference><Citation>Herold &#xa0;T, Jurinovic &#xa0;V, Arnreich &#xa0;C, et al. &#xa0;Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19. J Allergy Clin Immunol &#xa0;2020; 146:128&#x2013;36.e4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7233239</ArticleId><ArticleId IdType="pubmed">32425269</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu &#xa0;X, Han &#xa0;M, Li &#xa0;T, et al. &#xa0;Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A &#xa0;2020; 117:10970&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7245089</ArticleId><ArticleId IdType="pubmed">32350134</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh &#xa0;AK, Oks &#xa0;M, Husk &#xa0;G, et al. &#xa0;Impact of timing of tocilizumab use in hospitalized patients with SARS-CoV-2 infection. Respir Care &#xa0;2021; 66:1805&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9993783</ArticleId><ArticleId IdType="pubmed">34548407</ArticleId></ArticleIdList></Reference><Reference><Citation>Mungmunpuntipantip &#xa0;R, Wiwanitkit &#xa0;V. Timing of tocilizumab use and COVID-19. Respir Care &#xa0;2022; 67:381&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pubmed">35190482</ArticleId></ArticleIdList></Reference><Reference><Citation>Abidi &#xa0;E, El Nekidy &#xa0;WS, Alefishat &#xa0;E, et al. &#xa0;Tocilizumab and COVID-19: timing of administration and efficacy. Front Pharmacol &#xa0;2022; 13:825749.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8894855</ArticleId><ArticleId IdType="pubmed">35250575</ArticleId></ArticleIdList></Reference><Reference><Citation>RECOVERY Collabarative Group . Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet &#xa0;2021; 397:1637&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8084355</ArticleId><ArticleId IdType="pubmed">33933206</ArticleId></ArticleIdList></Reference><Reference><Citation>Price &#xa0;CC, Altice &#xa0;FL, Shyr &#xa0;Y, et al. &#xa0;Tocilizumab treatment for cytokine release syndrome in hospitalized patients with coronavirus disease 2019: survival and clinical outcomes. Chest &#xa0;2020; 158:1397&#x2013;408.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7831876</ArticleId><ArticleId IdType="pubmed">32553536</ArticleId></ArticleIdList></Reference><Reference><Citation>RECOVERY Collabarative Group; Horby &#xa0;P, Lim &#xa0;WS, et al. &#xa0;Dexamethasone in hospitalized patients with COVID-19. N Engl J Med &#xa0;2021; 384:693&#x2013;704.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7383595</ArticleId><ArticleId IdType="pubmed">32678530</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowe &#xa0;B, Xie &#xa0;Y, Al-Aly &#xa0;Z. Acute and postacute sequelae associated with SARS-CoV-2 reinfection. Nat Med &#xa0;2022; 28:2398&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9671810</ArticleId><ArticleId IdType="pubmed">36357676</ArticleId></ArticleIdList></Reference><Reference><Citation>Bosworth &#xa0;ML, Shenhuy &#xa0;B, Walker &#xa0;AS, et al. &#xa0;Risk of new-onset long COVID following reinfection with severe acute respiratory syndrome coronavirus 2: a community-based cohort study. Open Forum Infect Dis &#xa0;2023; 10:XXX&#x2013;XX.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10633780</ArticleId><ArticleId IdType="pubmed">37953820</ArticleId></ArticleIdList></Reference><Reference><Citation>Carfi &#xa0;A, Bernabei &#xa0;R, Landi &#xa0;F; Gemelli Against COVID-19 Post-Acute Care Study Group . Persistent symptoms in patients after acute COVID-19. JAMA &#xa0;2020; 324:603&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>Altmann &#xa0;DM, Boyton &#xa0;RJ. SARS-CoV-2 T cell immunity: specificity, function, durability, and role in protection. Sci Immunol &#xa0;2020; 5:eabd6160.</Citation><ArticleIdList><ArticleId IdType="pubmed">32680954</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre &#xa0;CH, Murray &#xa0;B, Varsavsky &#xa0;T, et al. &#xa0;Attributes and predictors of long COVID. Nat Med &#xa0;2021; 27:626&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7611399</ArticleId><ArticleId IdType="pubmed">33692530</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre &#xa0;CH, Murray &#xa0;B, Varsavsky &#xa0;T, et al. &#xa0;Author correction: attributes and predictors of long COVID. Nat Med &#xa0;2021; 27:1116.</Citation><ArticleIdList><ArticleId IdType="pubmed">34045738</ArticleId></ArticleIdList></Reference><Reference><Citation>Nehme &#xa0;M, Braillard &#xa0;O, Alcoba &#xa0;G, et al. &#xa0;COVID-19 symptoms: longitudinal evolution and persistence in outpatient settings. Ann Intern Med &#xa0;2021; 174:723&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7741180</ArticleId><ArticleId IdType="pubmed">33284676</ArticleId></ArticleIdList></Reference><Reference><Citation>Servier &#xa0;C, Porcher &#xa0;R, Pane &#xa0;I, Ravaud &#xa0;P, Tran &#xa0;VT. Trajectories of the evolution of post-COVID-19 condition, up to two years after symptoms onset. Int J Infect Dis &#xa0;2023; 133:67&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10176960</ArticleId><ArticleId IdType="pubmed">37182548</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowe &#xa0;B, Xie &#xa0;Y, Al-Aly &#xa0;Z. Postacute sequelae of COVID-19 at 2 years. Nat Med &#xa0;2023; 29:2347&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10504070</ArticleId><ArticleId IdType="pubmed">37605079</ArticleId></ArticleIdList></Reference><Reference><Citation>Boscolo-Rizzo &#xa0;P, Hummel &#xa0;T, Spinato &#xa0;G, et al. &#xa0;Olfactory and gustatory function 3 years after mild COVID-19&#x2014;a cohort psychophysical study. JAMA Otolaryngol Head Neck Surg &#xa0;2024; 150:79&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10636652</ArticleId><ArticleId IdType="pubmed">37943538</ArticleId></ArticleIdList></Reference><Reference><Citation>Demko &#xa0;ZO, Yu &#xa0;T, Mullapudi &#xa0;SK, et al. &#xa0;Two-year longitudinal study reveals that long COVID symptoms peak and quality of life nadirs at 6&#x2013;12 months postinfection. Open Forum Infect Dis &#xa0;2024; 11:XXX&#x2013;XX.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10917418</ArticleId><ArticleId IdType="pubmed">38449921</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriano &#xa0;JB, Murthy &#xa0;S, Marshall &#xa0;JC, Relan &#xa0;P, Diaz &#xa0;JV; WHO Clinical Case Definition Working Group on Post-COVID-19 Condition . A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis &#xa0;2022; 22:e102&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Burki &#xa0;T. Clinical case definition of post-COVID-19 condition in children: a good start, but improvements are needed. Lancet Respir Med &#xa0;2023; 11:314.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9991061</ArticleId><ArticleId IdType="pubmed">36898399</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaichana &#xa0;U, Man &#xa0;KKC, Chen &#xa0;A, et al. &#xa0;Definition of post-COVID-19 condition among published research studies. JAMA Netw Open &#xa0;2023; 6:e235856.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10077105</ArticleId><ArticleId IdType="pubmed">37017970</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerkhoff &#xa0;TJ, Charlton &#xa0;BT, Appelman &#xa0;B, van Vugt &#xa0;M, Wust &#xa0;RCI. Post COVID-19 condition: critical need for a clear definition and detailed pathophysiology. J Cachexia Sarcopenia Muscle &#xa0;2022; 13:2754&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9745497</ArticleId><ArticleId IdType="pubmed">36251474</ArticleId></ArticleIdList></Reference><Reference><Citation>
World Health Organization . Post COVID-19 condition (long COVID) 2024. https://www.who.int/europe/news-room/fact-sheets/item/post-COVID-19-condition. Accessed July 18, 2024.</Citation></Reference><Reference><Citation>
Centers for Disease Control and Prevention . Long COVID basics 2024. 2024. https://www.cdc.gov/covid/long-term-effects/index.html. Accessed July 18, 2024.</Citation></Reference><Reference><Citation>Kuchler &#xa0;T, G&#xfc;nthner &#xa0;R, Ribeiro &#xa0;A, et al. &#xa0;Persistent endothelial dysfunction in post-COVID-19 syndrome and its associations with symptom severity and chronic inflammation. Angiogenesis &#xa0;2023; 26:547&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10542303</ArticleId><ArticleId IdType="pubmed">37507580</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin &#xa0;K, Peluso &#xa0;MJ, Luo &#xa0;X, et al. &#xa0;Long COVID manifests with T cell dysregulation, inflammation and an uncoordinated adaptive immune response to SARS-CoV-2. Nat Immunol &#xa0;2024; 25:218&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10834368</ArticleId><ArticleId IdType="pubmed">38212464</ArticleId></ArticleIdList></Reference><Reference><Citation>Cervia-Hasler &#xa0;C, Br&#xfc;ningk &#xa0;SC, Hoch &#xa0;T, et al. &#xa0;Persistent complement dysregulation with signs of thromboinflammation in active long COVID. Science &#xa0;2024; 383:eadg7942.</Citation><ArticleIdList><ArticleId IdType="pubmed">38236961</ArticleId></ArticleIdList></Reference><Reference><Citation>Natarajan &#xa0;A, Zlitni &#xa0;S, Brooks &#xa0;EF, et al. &#xa0;Gastrointestinal symptoms and fecal shedding of SARS-CoV-2 RNA suggest prolonged gastrointestinal infection. Med &#xa0;2022; 3:371&#x2013;87.e9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9005383</ArticleId><ArticleId IdType="pubmed">35434682</ArticleId></ArticleIdList></Reference><Reference><Citation>Zollner &#xa0;A, Koch &#xa0;R, Jukic &#xa0;A, et al. &#xa0;Postacute COVID-19 is characterized by gut viral antigen persistence in inflammatory bowel diseases. Gastroenterology &#xa0;2022; 163:495&#x2013;506.e8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9057012</ArticleId><ArticleId IdType="pubmed">35508284</ArticleId></ArticleIdList></Reference><Reference><Citation>Antar &#xa0;AAR, Yu &#xa0;T, Demko &#xa0;ZO, et al. &#xa0;Long COVID brain fog and muscle pain are associated with longer time to clearance of SARS-CoV-2 RNA from the upper respiratory tract during acute infection. Front Immunol &#xa0;2023; 14:1147549.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10176965</ArticleId><ArticleId IdType="pubmed">37187756</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo &#xa0;W, He &#xa0;D, Liang &#xa0;C, et al. &#xa0;The persistence of SARS-CoV-2 in tissues and its association with long COVID symptoms: a cross-sectional cohort study in China. Lancet Infect Dis &#xa0;2024; 24:845&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">38663423</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein &#xa0;SR, Ramelli &#xa0;SC, Grazioli &#xa0;A, et al. &#xa0;SARS-CoV-2 infection and persistence in the human body and brain at autopsy. Nature &#xa0;2022; 612:758&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9749650</ArticleId><ArticleId IdType="pubmed">36517603</ArticleId></ArticleIdList></Reference><Reference><Citation>Su &#xa0;Q, Lau &#xa0;RI, Liu &#xa0;Q, et al. &#xa0;The gut microbiome associates with phenotypic manifestations of post-acute COVID-19 syndrome. Cell Host Microbe &#xa0;2024; 32:651&#x2013;60.e4.</Citation><ArticleIdList><ArticleId IdType="pubmed">38657605</ArticleId></ArticleIdList></Reference><Reference><Citation>Palis &#xa0;J, Yoder &#xa0;MC. Yolk-sac hematopoiesis: the first blood cells of mouse and man. Exp Hematol &#xa0;2001; 29:927&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">11495698</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet &#xa0;M, Skorniewska &#xa0;Z, Hampshire &#xa0;A, et al. &#xa0;Acute blood biomarker profiles predict cognitive deficits 6 and 12 months after COVID-19 hospitalization. Nat Med &#xa0;2023; 29:2498&#x2013;508.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10579097</ArticleId><ArticleId IdType="pubmed">37653345</ArticleId></ArticleIdList></Reference><Reference><Citation>Venkataramani &#xa0;V, Winkler &#xa0;F. Cognitive deficits in long COVID-19. N Engl J Med &#xa0;2022; 387:1813&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">36351274</ArticleId></ArticleIdList></Reference><Reference><Citation>Braga &#xa0;J, Lepra &#xa0;M, Kish &#xa0;SJ, et al. &#xa0;Neuroinflammation after COVID-19 with persistent depressive and cognitive symptoms. JAMA Psychiatry &#xa0;2023; 80:787&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10233457</ArticleId><ArticleId IdType="pubmed">37256580</ArticleId></ArticleIdList></Reference><Reference><Citation>Etter &#xa0;MM, Martins &#xa0;TA, Kulsvehagen &#xa0;L, et al. &#xa0;Severe neuro-COVID is associated with peripheral immune signatures, autoimmunity and neurodegeneration: a prospective cross-sectional study. Nat Commun &#xa0;2022; 13:6777.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9645766</ArticleId><ArticleId IdType="pubmed">36351919</ArticleId></ArticleIdList></Reference><Reference><Citation>Campabadal &#xa0;A, Oltra &#xa0;J, Junqu&#xe9; &#xa0;C, et al. &#xa0;Structural brain changes in post-acute COVID-19 patients with persistent olfactory dysfunction. Ann Clin Transl Neurol &#xa0;2023; 10:195&#x2013;203.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9878006</ArticleId><ArticleId IdType="pubmed">36525472</ArticleId></ArticleIdList></Reference><Reference><Citation>Finlay &#xa0;JB, Brann &#xa0;DH, Abi Hachem &#xa0;R, et al. &#xa0;Persistent post&#x2013;COVID-19 smell loss is associated with immune cell infiltration and altered gene expression in olfactory epithelium. Sci Transl Med &#xa0;2022; 14:eadd0484.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10317309</ArticleId><ArticleId IdType="pubmed">36542694</ArticleId></ArticleIdList></Reference><Reference><Citation>Greene &#xa0;C, Connolly &#xa0;R, Brennan &#xa0;D, et al. &#xa0;Blood&#x2013;brain barrier disruption and sustained systemic inflammation in individuals with long COVID-associated cognitive impairment. Nat Neurosci &#xa0;2024; 27:421&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10917679</ArticleId><ArticleId IdType="pubmed">38388736</ArticleId></ArticleIdList></Reference><Reference><Citation>Llados &#xa0;G, Massanella &#xa0;M, Coll-Fern&#xe1;ndez &#xa0;R, et al. &#xa0;Vagus nerve dysfunction in the post-COVID-19 condition: a pilot cross-sectional study. Clin Microbiol Infect &#xa0;2024; 30:515&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">37984511</ArticleId></ArticleIdList></Reference><Reference><Citation>Guarnieri &#xa0;JW, Dybas &#xa0;JM, Fazelinia &#xa0;H, et al. &#xa0;Core mitochondrial genes are down-regulated during SARS-CoV-2 infection of rodent and human hosts. Sci Transl Med &#xa0;2023; 15:eabq1533.</Citation><ArticleIdList><ArticleId IdType="pubmed">37556555</ArticleId></ArticleIdList></Reference><Reference><Citation>Appelman &#xa0;B, Charlton &#xa0;BT, Goulding &#xa0;RP, et al. &#xa0;Muscle abnormalities worsen after post-exertional malaise in long COVID. Nat Commun &#xa0;2024; 15:17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10766651</ArticleId><ArticleId IdType="pubmed">38177128</ArticleId></ArticleIdList></Reference><Reference><Citation>Tryfonos &#xa0;A, Pourhamidi &#xa0;K, J&#xf6;rn&#xe5;ker &#xa0;G, et al. &#xa0;Functional limitations and exercise intolerance in patients with post-COVID condition: a randomized crossover clinical trial. JAMA Netw Open &#xa0;2024; 7:e244386.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11192186</ArticleId><ArticleId IdType="pubmed">38573638</ArticleId></ArticleIdList></Reference><Reference><Citation>Grune &#xa0;J, Bajpai &#xa0;G, Ocak &#xa0;PT, et al. &#xa0;Virus-induced acute respiratory distress syndrome causes cardiomyopathy through eliciting inflammatory responses in the heart. Circulation &#xa0;2024; 150:49&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11216864</ArticleId><ArticleId IdType="pubmed">38506045</ArticleId></ArticleIdList></Reference><Reference><Citation>Alrajhi &#xa0;NN. Post-COVID-19 pulmonary fibrosis: an ongoing concern. Ann Thorac Med &#xa0;2023; 18:173&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10697304</ArticleId><ArticleId IdType="pubmed">38058790</ArticleId></ArticleIdList></Reference><Reference><Citation>Dondaine &#xa0;T, Ruthmann &#xa0;F, Vuotto &#xa0;F, et al. &#xa0;Long-term cognitive impairments following COVID-19: a possible impact of hypoxia. J Neurol &#xa0;2022; 269:3982&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8944178</ArticleId><ArticleId IdType="pubmed">35325308</ArticleId></ArticleIdList></Reference><Reference><Citation>Thaweethai &#xa0;T, Jolley &#xa0;SE, Karlson &#xa0;EW, et al. &#xa0;Development of a definition of postacute sequelae of SARS-CoV-2 infection. JAMA &#xa0;2023; 329:1934&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10214179</ArticleId><ArticleId IdType="pubmed">37278994</ArticleId></ArticleIdList></Reference><Reference><Citation>Landry &#xa0;M, Bornstein &#xa0;S, Nagaraj &#xa0;N, et al. &#xa0;Postacute sequelae of SARS-CoV-2 in university setting. |Emerg Infect Dis &#xa0;2023; 29:519&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9973677</ArticleId><ArticleId IdType="pubmed">36703253</ArticleId></ArticleIdList></Reference><Reference><Citation>Atchison &#xa0;CJ, Whitaker &#xa0;M, Donnelly &#xa0;CA, et al. &#xa0;Characteristics and predictors of persistent symptoms post-COVID-19 in children and young people: a large community cross-sectional study in England. Arch Dis Child &#xa0;2023; 108:e12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10313975</ArticleId><ArticleId IdType="pubmed">36863848</ArticleId></ArticleIdList></Reference><Reference><Citation>Selvakumar &#xa0;J, Havdal &#xa0;LB, Drevvatne &#xa0;M, et al. &#xa0;Prevalence and characteristics associated with post&#x2013;COVID-19 condition among nonhospitalized adolescents and young adults. JAMA Netw Open &#xa0;2023; 6:e235763.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10064252</ArticleId><ArticleId IdType="pubmed">36995712</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruickshank &#xa0;M, Brazzelli &#xa0;M, Manson &#xa0;P, Torrance &#xa0;N, Grant &#xa0;A. What is the impact of long-term COVID-19 on workers in healthcare settings? A rapid systematic review of current evidence. PLoS One &#xa0;2024; 19:e0299743.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10914278</ArticleId><ArticleId IdType="pubmed">38442116</ArticleId></ArticleIdList></Reference><Reference><Citation>Muller &#xa0;SA, Isaaka &#xa0;L, Mumm &#xa0;R, et al. &#xa0;Prevalence and risk factors for long COVID and post-COVID-19 condition in Africa: a systematic review. Lancet Glob Health &#xa0;2023; 11:e1713&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">37858583</ArticleId></ArticleIdList></Reference><Reference><Citation>Frallonardo &#xa0;L, Segala &#xa0;FV, Chhaganlal &#xa0;KD, et al. &#xa0;Incidence and burden of long COVID in Africa: a systematic review and meta-analysis. Sci Rep &#xa0;2023; 13:21482.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10700349</ArticleId><ArticleId IdType="pubmed">38057338</ArticleId></ArticleIdList></Reference><Reference><Citation>DeVries &#xa0;A, Shambhu &#xa0;S, Sloop &#xa0;S, Overhage &#xa0;JM. One-year adverse outcomes among US adults with post&#x2013;COVID-19 condition vs those without COVID-19 in a large commercial insurance database. JAMA Health Forum &#xa0;2023; 4:e230010.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9984976</ArticleId><ArticleId IdType="pubmed">36867420</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsampasian &#xa0;V, Elghazaly &#xa0;H, Chattopadhyay &#xa0;R, et al. &#xa0;Risk factors associated with post&#x2212;COVID-19 condition: a systematic review and meta-analysis. JAMA Intern Med &#xa0;2023; 183:566&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10037203</ArticleId><ArticleId IdType="pubmed">36951832</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie &#xa0;Y, Choi &#xa0;T, Al-Aly &#xa0;Z. Association of treatment with nirmatrelvir and the risk of post&#x2013;COVID-19 condition. JAMA Intern Med &#xa0;2023; 183:554&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10037200</ArticleId><ArticleId IdType="pubmed">36951829</ArticleId></ArticleIdList></Reference><Reference><Citation>L Mandel &#xa0;H, Colleen &#xa0;G, Abedian &#xa0;S, et al. &#xa0;Risk of post-acute sequelae of SARS-CoV-2 infection associated with pre-coronavirus disease obstructive sleep apnea diagnoses: an electronic health record-based analysis from the RECOVER initiative. Sleep &#xa0;2023; 46:zsad126.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10485569</ArticleId><ArticleId IdType="pubmed">37166330</ArticleId></ArticleIdList></Reference><Reference><Citation>Boekel &#xa0;L, Atiqi &#xa0;S, Leeuw &#xa0;M, et al. &#xa0;Post-COVID condition in patients with inflammatory rheumatic diseases: a prospective cohort study in The Netherlands. Lancet Rheumatol &#xa0;2023; 5:e375&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10292827</ArticleId><ArticleId IdType="pubmed">37398978</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor &#xa0;K, Pearson &#xa0;M, Das &#xa0;S, et al. &#xa0;Genetic risk factors for severe and fatigue dominant long COVID and commonalities with ME/CFS identified by combinatorial analysis. J Transl Med &#xa0;2023; 21:775.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10621206</ArticleId><ArticleId IdType="pubmed">37915075</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottlieb &#xa0;M, Wang &#xa0;RC, Yu &#xa0;H, et al. &#xa0;Severe fatigue and persistent symptoms at 3 months following severe acute respiratory syndrome coronavirus 2 infections during the pre-Delta, Delta, and Omicron time periods: a multicenter prospective cohort study. Clin Infect Dis &#xa0;2023; 76:1930&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10249989</ArticleId><ArticleId IdType="pubmed">36705268</ArticleId></ArticleIdList></Reference><Reference><Citation>Altmann &#xa0;DM, Whettlock &#xa0;EM, Liu &#xa0;S, Arachchillage &#xa0;DJ, Boyton &#xa0;RJ. The immunology of long COVID. Nat Rev Immunol &#xa0;2023; 23:618&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">37433988</ArticleId></ArticleIdList></Reference><Reference><Citation>Krishna &#xa0;BA, Lim &#xa0;EY, Metaxaki &#xa0;M, et al. &#xa0;Spontaneous, persistent, T cell&#x2013;dependent IFN-&#x3b3; release in patients who progress to long COVID. Sci Adv &#xa0;2024; 10:eadi9379.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10881041</ArticleId><ArticleId IdType="pubmed">38381822</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoeggerl &#xa0;AD, Nunhofer &#xa0;V, Lauth &#xa0;W, et al. &#xa0;Epstein-Barr virus reactivation is not causative for post-COVID-19-syndrome in individuals with asymptomatic or mild SARS-CoV-2 disease course. BMC Infect Dis &#xa0;2023; 23:800.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10652630</ArticleId><ArticleId IdType="pubmed">37968601</ArticleId></ArticleIdList></Reference><Reference><Citation>Swank &#xa0;Z, Senussi &#xa0;Y, Manickas-Hill &#xa0;Z, et al. &#xa0;Persistent circulating severe acute respiratory syndrome coronavirus 2 spike is associated with post-acute coronavirus disease 2019 sequelae. Clin Infect Dis &#xa0;2023; 76:e487&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10169416</ArticleId><ArticleId IdType="pubmed">36052466</ArticleId></ArticleIdList></Reference><Reference><Citation>Phetsouphanh &#xa0;C, Darley &#xa0;DR, Wilson &#xa0;DB, et al. &#xa0;Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat Immunol &#xa0;2022; 23:210&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">35027728</ArticleId></ArticleIdList></Reference><Reference><Citation>LaVergne &#xa0;S, LaVergne &#xa0;S, Dutt &#xa0;T, et al. &#xa0;78. Longitudinal analysis of T cells in COVID-19 survivors with post-acute sequelae of COVID-19 reveals associations between individual symptoms and inflammatory indexes. Open Forum Infect Dis &#xa0;2022; 9:XXX&#x2013;XX.</Citation></Reference><Reference><Citation>Hanson &#xa0;AL, Mul&#xe8; &#xa0;MP, Ruffieux &#xa0;H, et al. &#xa0;Iron dysregulation and inflammatory stress erythropoiesis associates with long-term outcome of COVID-19. Nat Immunol &#xa0;2024; 25:471&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10907301</ArticleId><ArticleId IdType="pubmed">38429458</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong &#xa0;AC, Devason &#xa0;AS, Umana &#xa0;IC, et al. &#xa0;Serotonin reduction in post-acute sequelae of viral infection. Cell &#xa0;2023; 186:4851&#x2013;67.e20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11227373</ArticleId><ArticleId IdType="pubmed">37848036</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu &#xa0;E, Xie &#xa0;Y, Al-Aly &#xa0;Z. Long-term gastrointestinal outcomes of COVID-19. Nat Commun &#xa0;2023; 14:983.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9992516</ArticleId><ArticleId IdType="pubmed">36882400</ArticleId></ArticleIdList></Reference><Reference><Citation>Gutman &#xa0;EG, Salvio &#xa0;AL, Fernandes &#xa0;RA, et al. &#xa0;Long COVID: plasma levels of neurofilament light chain in mild COVID-19 patients with neurocognitive symptoms. Mol Psychiatry. &#xa0;2024; Apr 27.</Citation><ArticleIdList><ArticleId IdType="pubmed">38678084</ArticleId></ArticleIdList></Reference><Reference><Citation>Roca-Fernandez &#xa0;A, Wamil &#xa0;M, Telford &#xa0;A, et al. &#xa0;Cardiac abnormalities in long COVID 1-year post-SARS-CoV-2 infection. Open Heart &#xa0;2023; 10:e002241.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9950586</ArticleId><ArticleId IdType="pubmed">36822818</ArticleId></ArticleIdList></Reference><Reference><Citation>Seeley &#xa0;MC, Gallagher &#xa0;C, Ong &#xa0;E, et al. &#xa0;High incidence of autonomic dysfunction and postural orthostatic tachycardia syndrome in patients with long COVID: implications for management and health care planning. Am J Med. &#xa0;2023; Jun 29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10307671</ArticleId><ArticleId IdType="pubmed">37391116</ArticleId></ArticleIdList></Reference><Reference><Citation>Delogu &#xa0;AB, Aliberti &#xa0;C, Birritella &#xa0;L, et al. &#xa0;Autonomic cardiac function in children and adolescents with long COVID: a case-controlled study. Eur J Pediatr &#xa0;2024; 183:2375&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11035407</ArticleId><ArticleId IdType="pubmed">38446228</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez-Hermosillo G &#xa0;JA, Galarza &#xa0;EJ, Ferm&#xed;n &#xa0;OV, et al. &#xa0;Exaggerated blood pressure elevation in response to orthostatic challenge, a post-acute sequelae of SARS-CoV-2 infection (PASC) after hospitalization. Auton Neurosci &#xa0;2023; 247:103094.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10121145</ArticleId><ArticleId IdType="pubmed">37137186</ArticleId></ArticleIdList></Reference><Reference><Citation>Mooren &#xa0;FC, B&#xf6;ckelmann &#xa0;I, Waranski &#xa0;M, et al. &#xa0;Autonomic dysregulation in long-term patients suffering from post-COVID-19 syndrome assessed by heart rate variability. Sci Rep &#xa0;2023; 13:15814.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10516975</ArticleId><ArticleId IdType="pubmed">37739977</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee &#xa0;C, Greenwood &#xa0;DC, Master &#xa0;H, et al. &#xa0;Prevalence of orthostatic intolerance in long COVID clinic patients and healthy volunteers: a multicenter study. J Med Virol &#xa0;2024; 96:e29486.</Citation><ArticleIdList><ArticleId IdType="pubmed">38456315</ArticleId></ArticleIdList></Reference><Reference><Citation>Palau &#xa0;P, Calvo &#xa0;B, Sastre &#xa0;C, et al. &#xa0;Unraveling the mechanisms behind exercise intolerance and recovery in long COVID. Am J Med. &#xa0;In press.</Citation><ArticleIdList><ArticleId IdType="pubmed">38648998</ArticleId></ArticleIdList></Reference><Reference><Citation>Baldi &#xa0;F, De Rose &#xa0;C, Mariani &#xa0;F, et al. &#xa0;Cardiopulmonary exercise testing in children with long COVID: a case-controlled study. Pediatr Infect Dis J &#xa0;2024; 43:795&#x2013;802.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11250093</ArticleId><ArticleId IdType="pubmed">38713816</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie &#xa0;Y, Xu &#xa0;E, Bowe &#xa0;B, Al-Aly &#xa0;Z. Long-term cardiovascular outcomes of COVID-19. Nat Med &#xa0;2022; 28:583&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8938267</ArticleId><ArticleId IdType="pubmed">35132265</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsoularis &#xa0;I, Jerndal &#xa0;H, Kalucza &#xa0;S, Lindmark &#xa0;K, Fonseca-Rodr&#xed;guez &#xa0;O, Connolly &#xa0;A-MF. Risk of arrhythmias following COVID-19: nationwide self-controlled case series and matched cohort study. Eur Heart Open &#xa0;2023; 3:oead120.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10711544</ArticleId><ArticleId IdType="pubmed">38089855</ArticleId></ArticleIdList></Reference><Reference><Citation>Patton &#xa0;MJ, Benson &#xa0;D, Robison &#xa0;SW, et al. &#xa0;Characteristics and determinants of pulmonary long COVID. JCI Insight &#xa0;2024; 9:e177518.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11141907</ArticleId><ArticleId IdType="pubmed">38652535</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim &#xa0;JT, Liang En &#xa0;W, Tay &#xa0;AT, et al. &#xa0;Long-term cardiovascular, cerebrovascular, and other thrombotic complications in COVID-19 survivors: a retrospective cohort study. Clin Infect Dis &#xa0;2024; 78:70&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10810710</ArticleId><ArticleId IdType="pubmed">37746872</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoubkhani &#xa0;D, Khunti &#xa0;K, Nafilyan &#xa0;V, et al. &#xa0;Post-COVID syndrome in individuals admitted to hospital with COVID-19: retrospective cohort study. BMJ &#xa0;2021; 372:n693.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8010267</ArticleId><ArticleId IdType="pubmed">33789877</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet &#xa0;M, Geddes &#xa0;JR, Husain &#xa0;M, Luciano &#xa0;S, Harrison &#xa0;PJ. 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. Lancet Psychiatry &#xa0;2021; 8:416&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8023694</ArticleId><ArticleId IdType="pubmed">33836148</ArticleId></ArticleIdList></Reference><Reference><Citation>Daugherty &#xa0;SE, Guo &#xa0;Y, Heath &#xa0;K, et al. &#xa0;Risk of clinical sequelae after the acute phase of SARS-CoV-2 infection: retrospective cohort study. BMJ &#xa0;2021; 373:n1098.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8132065</ArticleId><ArticleId IdType="pubmed">34011492</ArticleId></ArticleIdList></Reference><Reference><Citation>Hastie &#xa0;CE, Lowe &#xa0;DJ, McAuley &#xa0;A, et al. &#xa0;Outcomes among confirmed cases and a matched comparison group in the Long-COVID in Scotland study. Nat Commun &#xa0;2022; 13:5663.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9556711</ArticleId><ArticleId IdType="pubmed">36224173</ArticleId></ArticleIdList></Reference><Reference><Citation>Hastie &#xa0;CE, Lowe &#xa0;DJ, McAuley &#xa0;A, et al. &#xa0;Author correction: outcomes among confirmed cases and a matched comparison group in the Long-COVID in Scotland study. Nat Commun &#xa0;2022; 13:6540.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9626587</ArticleId><ArticleId IdType="pubmed">36319644</ArticleId></ArticleIdList></Reference><Reference><Citation>Kenny &#xa0;G, McCann &#xa0;K, O'Brien &#xa0;C, et al. &#xa0;Identification of distinct long COVID clinical phenotypes through cluster analysis of self-reported symptoms. Open Forum Infect Dis &#xa0;2022; 9:XXX&#x2013;XX.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8900926</ArticleId><ArticleId IdType="pubmed">35265728</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian &#xa0;A, Sehgal &#xa0;K, Gupta &#xa0;A, et al. &#xa0;Post-acute COVID-19 syndrome. Nat Med &#xa0;2021; 27:601&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Reese &#xa0;JT, Blau &#xa0;H, Casiraghi &#xa0;E, et al. &#xa0;Generalizable long COVID subtypes: findings from the NIH N3C and RECOVER programs. EBioMedicine &#xa0;2023; 87:104413..</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9769411</ArticleId><ArticleId IdType="pubmed">36563487</ArticleId></ArticleIdList></Reference><Reference><Citation>Talla &#xa0;A, Vasaikar &#xa0;SV, Szeto &#xa0;GL, et al. &#xa0;Persistent serum protein signatures define an inflammatory subcategory of long COVID. Nat Commun &#xa0;2023; 14:3417.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10252177</ArticleId><ArticleId IdType="pubmed">37296110</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto &#xa0;MD, Downs &#xa0;CA, Huang &#xa0;Y, et al. &#xa0;A distinct symptom pattern emerges for COVID-19 long-haul: a nationwide study. Sci Rep &#xa0;2022; 12:15905.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9508141</ArticleId><ArticleId IdType="pubmed">36151129</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang &#xa0;H, Zang &#xa0;C, Xu &#xa0;Z, et al. &#xa0;Data-driven identification of post-acute SARS-CoV-2 infection subphenotypes. Nat Med &#xa0;2023; 29:226&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9873564</ArticleId><ArticleId IdType="pubmed">36456834</ArticleId></ArticleIdList></Reference><Reference><Citation>Kenny &#xa0;G, McCann &#xa0;K, O'Brien &#xa0;C, et al. &#xa0;77. Demonstration of stable clusters of symptoms in long COVID. Open Forum Infect Dis &#xa0;2022; 9:XXX&#x2013;XX.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8900926</ArticleId><ArticleId IdType="pubmed">35265728</ArticleId></ArticleIdList></Reference><Reference><Citation>Gentilotti &#xa0;E, G&#xf3;rska &#xa0;A, Tami &#xa0;A, et al. &#xa0;Clinical phenotypes and quality of life to define post-COVID-19 syndrome: a cluster analysis of the multinational, prospective ORCHESTRA cohort. EClinicalMedicine &#xa0;2023; 62:102107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10466236</ArticleId><ArticleId IdType="pubmed">37654668</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottlieb &#xa0;M, Spatz &#xa0;ES, Yu &#xa0;H, et al. &#xa0;Long COVID clinical phenotypes up to 6 months after infection identified by latent class analysis of self-reported symptoms. Open Forum Infect Dis &#xa0;2023; 10:XXX&#x2013;XX.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10327879</ArticleId><ArticleId IdType="pubmed">37426952</ArticleId></ArticleIdList></Reference><Reference><Citation>
Centers for Disease Control and Prevention . Myalgic encephalomyelitis. Chronic fatigue syndrome 2024. 2024. https://www.cdc.gov/me-cfs/about/index.html. Accessed July 18, 2024.</Citation></Reference><Reference><Citation>Walker &#xa0;S, Goodfellow &#xa0;H, Pookarnjanamorakot &#xa0;P, et al. &#xa0;Impact of fatigue as the primary determinant of functional limitations among patients with post-COVID-19 syndrome: a cross-sectional observational study. BMJ Open &#xa0;2023; 13:e069217.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10335413</ArticleId><ArticleId IdType="pubmed">37286327</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford &#xa0;ND, Slaughter &#xa0;D, Edwards &#xa0;D, et al. &#xa0;Long COVID and significant activity limitation among adults, by age&#x2014;United States, June 1&#x2013;13, 2022, to June 7&#x2013;19, 2023. MMWR Morb Mortal Wkly Rep &#xa0;2023; 72:866&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10415000</ArticleId><ArticleId IdType="pubmed">37561665</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizrahi &#xa0;B, Sudry &#xa0;T, Flaks-Manov &#xa0;N, et al. &#xa0;Long COVID outcomes at one year after mild SARS-CoV-2 infection: nationwide cohort study. BMJ &#xa0;2023; 380:e072529.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9832503</ArticleId><ArticleId IdType="pubmed">36631153</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang &#xa0;W, Wang &#xa0;CY, Wang &#xa0;SI, Wei &#xa0;JC. Long-term cardiovascular outcomes in COVID-19 survivors among non-vaccinated population: a retrospective cohort study from the TriNetX US collaborative networks. EClinicalMedicine &#xa0;2022; 53:101619.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9366236</ArticleId><ArticleId IdType="pubmed">35971425</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed &#xa0;AI, Al Rifai &#xa0;M, Alahdab &#xa0;F, et al. &#xa0;Coronary microvascular health in symptomatic patients with prior COVID-19 infection: an updated analysis. Eur Heart J Cardiovasc Imaging &#xa0;2023; 24:1544&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10610774</ArticleId><ArticleId IdType="pubmed">37254693</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang &#xa0;V, Fisher &#xa0;M, Hou &#xa0;W, Zhang &#xa0;L, Duong &#xa0;TQ. Incidence of new-onset hypertension post-COVID-19: comparison with influenza. Hypertension &#xa0;2023; 80:2135&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">37602375</ArticleId></ArticleIdList></Reference><Reference><Citation>Rinaldi &#xa0;L, Rigo &#xa0;S, Pani &#xa0;M, et al. &#xa0;Long-COVID autonomic syndrome in working age and work ability impairment. Sci Rep &#xa0;2024; 14:11835.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11116376</ArticleId><ArticleId IdType="pubmed">38782998</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng &#xa0;M, Wei &#xa0;R, Wu &#xa0;Y, et al. &#xa0;Long-term risks of respiratory diseases in patients infected with SARS-CoV-2: a longitudinal, population-based cohort study. EClinicalMedicine &#xa0;2024; 69:102500.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10882104</ArticleId><ArticleId IdType="pubmed">38389713</ArticleId></ArticleIdList></Reference><Reference><Citation>Yanachkova &#xa0;V, Stankova &#xa0;T, Staynova &#xa0;R. Thyroid dysfunction as a long-term post-COVID-19 complication in mild-to-moderate COVID-19. Biotechnol Biotechnol Equip &#xa0;2023; 37:194&#x2013;202.</Citation></Reference><Reference><Citation>Chourasia &#xa0;P, Goyal &#xa0;L, Kansal &#xa0;D, et al. &#xa0;Risk of new-onset diabetes mellitus as a post-COVID-19 condition and possible mechanisms: a scoping review. J Clin Med &#xa0;2023; 12:1159.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9917823</ArticleId><ArticleId IdType="pubmed">36769807</ArticleId></ArticleIdList></Reference><Reference><Citation>Stavem &#xa0;K, Einvik &#xa0;G, Lundqvist &#xa0;C. Cognitive impairment 13 months after hospitalization for COVID-19. Open Forum Infect Dis &#xa0;2022; 9:XXX&#x2013;XX.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9330249</ArticleId><ArticleId IdType="pubmed">35912021</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheetham &#xa0;NJ, Penfold &#xa0;R, Giunchiglia &#xa0;V, et al. &#xa0;The effects of COVID-19 on cognitive performance in a community-based cohort: a COVID Symptom Study Biobank prospective cohort study. EClinicalMedicine &#xa0;2023; 62:102086.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10466229</ArticleId><ArticleId IdType="pubmed">37654669</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao &#xa0;S, Martin &#xa0;EM, Reuken &#xa0;PA, et al. &#xa0;Long COVID is associated with severe cognitive slowing: a multicentre cross-sectional study. EClinicalMedicine &#xa0;2024; 68:102434.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10839583</ArticleId><ArticleId IdType="pubmed">38318123</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartung &#xa0;TJ, Bahmer &#xa0;T, Chaplinskaya-Sobol &#xa0;I, et al. &#xa0;Predictors of non-recovery from fatigue and cognitive deficits after COVID-19: a prospective, longitudinal, population-based study. EClinicalMedicine &#xa0;2024; 69:102456.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10847699</ArticleId><ArticleId IdType="pubmed">38333368</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellingjord-Dale &#xa0;M, Brunvoll &#xa0;SH, Soraas &#xa0;A. Prospective memory assessment before and after COVID-19. N Engl J Med &#xa0;2024; 390:863&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11156183</ArticleId><ArticleId IdType="pubmed">38416436</ArticleId></ArticleIdList></Reference><Reference><Citation>Serrano del Pueblo &#xa0;VM, Serrano-Heras &#xa0;G, Romero S&#xe1;nchez &#xa0;CM, et al. &#xa0;Brain and cognitive changes in patients with long COVID compared with infection-recovered control subjects. Brain. &#xa0;In press.</Citation><ArticleIdList><ArticleId IdType="pubmed">38562097</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampshire &#xa0;A, Azor &#xa0;A, Atchison &#xa0;C, et al. &#xa0;Cognition and memory after COVID-19 in a large community sample. N Engl J Med &#xa0;2024; 390:806&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7615803</ArticleId><ArticleId IdType="pubmed">38416429</ArticleId></ArticleIdList></Reference><Reference><Citation>Delgado-Alonso &#xa0;C, Delgado-Alvarez &#xa0;A, D&#xed;ez-Cirarda &#xa0;M, et al. &#xa0;Cognitive profile in multiple sclerosis and post-COVID condition: a comparative study using a unified taxonomy. Sci Rep &#xa0;2024; 14:9806.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11059260</ArticleId><ArticleId IdType="pubmed">38684843</ArticleId></ArticleIdList></Reference><Reference><Citation>Golla &#xa0;R, Vuyyuru &#xa0;S, Kante &#xa0;B, et al. &#xa0;Long-term gastrointestinal sequelae following COVID-19: a prospective follow-up cohort study. Clin Gastroenterol Hepatol &#xa0;2023; 21:789&#x2013;96.e1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9584755</ArticleId><ArticleId IdType="pubmed">36273799</ArticleId></ArticleIdList></Reference><Reference><Citation>Hebert &#xa0;KJ, Matta &#xa0;R, Horns &#xa0;JJ, et al. &#xa0;Prior COVID-19 infection associated with increased risk of newly diagnosed erectile dysfunction. Int J Impot Res &#xa0;2023; 36:521&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10015534</ArticleId><ArticleId IdType="pubmed">36922696</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu &#xa0;AQ, Chiu &#xa0;PK-F, Yee &#xa0;SC-H, Ng &#xa0;C-F, Teoh &#xa0;JY-C. SARS-CoV-2 infection correlates with male benign prostatic hyperplasia deterioration. J Intern Med &#xa0;2023; 294:775&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">37849423</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang &#xa0;G, Zhi &#xa0;W, Ye &#xa0;F, et al. &#xa0;Systematic analyses of the factors influencing sperm quality in patients with SARS-CoV-2 infection. Sci Rep &#xa0;2024; 14:8132.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10999436</ArticleId><ArticleId IdType="pubmed">38584153</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollack &#xa0;B, von Saltza &#xa0;E, McCorkell &#xa0;L, et al. &#xa0;Female reproductive health impacts of long COVID and associated illnesses including ME/CFS, POTS, and connective tissue disorders: a literature review. Front Rehabil Sci &#xa0;2023; 4:1122673.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10208411</ArticleId><ArticleId IdType="pubmed">37234076</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang &#xa0;R, Yen-Ting Chen &#xa0;T, Wang &#xa0;S-I, et al. &#xa0;Risk of autoimmune diseases in patients with COVID-19: a retrospective cohort study. EClinicalMedicine &#xa0;2023; 56:101783.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9830133</ArticleId><ArticleId IdType="pubmed">36643619</ArticleId></ArticleIdList></Reference><Reference><Citation>Tesch &#xa0;F, Ehm &#xa0;F, Vivirito &#xa0;A, et al. &#xa0;Incident autoimmune diseases in association with SARS-CoV-2 infection: a matched cohort study. Clin Rheumatol &#xa0;2023; 42:2905&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10497688</ArticleId><ArticleId IdType="pubmed">37335408</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong &#xa0;X, Lui &#xa0;DTW, Chung &#xa0;MSH, et al. &#xa0;Incidence of diabetes following COVID-19 vaccination and SARS-CoV-2 infection in Hong Kong: a population-based cohort study. PLoS Med &#xa0;2023; 20:e1004274.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10406181</ArticleId><ArticleId IdType="pubmed">37486927</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng &#xa0;K, Li &#xa0;X, Yang &#xa0;D, et al. &#xa0;Risk of autoimmune diseases following COVID-19 and the potential protective effect from vaccination: a population-based cohort study. EClinicalMedicine &#xa0;2023; 63:102154.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10458663</ArticleId><ArticleId IdType="pubmed">37637754</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh &#xa0;J, Lee &#xa0;M, Kim &#xa0;M, et al. &#xa0;Incident allergic diseases in post-COVID-19 condition: multinational cohort studies from South Korea, Japan and the UK. Nat Commun &#xa0;2024; 15:2830.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10987608</ArticleId><ArticleId IdType="pubmed">38565542</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao &#xa0;D, Cheng &#xa0;S, Tsui &#xa0;FR, Mathur &#xa0;MB, Wang &#xa0;C-HJ. The risk of aircraft-acquired SARS-CoV-2 transmission during commercial flights: a systematic review. Int J Environ Res Public Health &#xa0;2024; 21:654.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11203943</ArticleId><ArticleId IdType="pubmed">38928901</ArticleId></ArticleIdList></Reference><Reference><Citation>Wanga &#xa0;V, Chevinsky &#xa0;JR, Dimitrov &#xa0;LV, et al. &#xa0;Long-term symptoms among adults tested for SARS-CoV-2&#x2014;United States, January 2020-April 2021. MMWR Morb Mortal Wkly Rep &#xa0;2021; 70:1235&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8437054</ArticleId><ArticleId IdType="pubmed">34499626</ArticleId></ArticleIdList></Reference><Reference><Citation>Azzolini &#xa0;E, Levi &#xa0;R, Sarti &#xa0;R, et al. &#xa0;Association between BNT162b2 vaccination and long COVID after infections not requiring hospitalization in health care workers. JAMA &#xa0;2022; 328:676&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9250078</ArticleId><ArticleId IdType="pubmed">35796131</ArticleId></ArticleIdList></Reference><Reference><Citation>Notarte &#xa0;KI, Catahay &#xa0;JA, Velasco &#xa0;JV, et al. &#xa0;Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: a systematic review. EClinicalMedicine &#xa0;2022; 53:101624.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9417563</ArticleId><ArticleId IdType="pubmed">36051247</ArticleId></ArticleIdList></Reference><Reference><Citation>Marra &#xa0;AR, Kobayashi &#xa0;T, Suzuki &#xa0;H, et al. &#xa0;The effectiveness of coronavirus disease 2019 (COVID-19) vaccine in the prevention of post-COVID-19 conditions: a systematic literature review and meta-analysis. Antimicrob Steward Healthc Epidemiol &#xa0;2022; 2:e192.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9726631</ArticleId><ArticleId IdType="pubmed">36505947</ArticleId></ArticleIdList></Reference><Reference><Citation>Richard &#xa0;SA, Pollett &#xa0;SD, Fries &#xa0;AC, et al. &#xa0;Persistent COVID-19 symptoms at 6 months after onset and the role of vaccination before or after SARS-CoV-2 infection. JAMA Netw Open &#xa0;2023; 6:e2251360.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9857077</ArticleId><ArticleId IdType="pubmed">36652247</ArticleId></ArticleIdList></Reference><Reference><Citation>Marra &#xa0;AR, Kobayashi &#xa0;T, Callado &#xa0;GY, et al. &#xa0;The effectiveness of COVID-19 vaccine in the prevention of post-COVID conditions: a systematic literature review and meta-analysis of the latest research. Antimicrob Steward Healthc Epidemiol &#xa0;2023; 3:e168.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10644173</ArticleId><ArticleId IdType="pubmed">38028898</ArticleId></ArticleIdList></Reference><Reference><Citation>Yousaf &#xa0;AR, Mak &#xa0;J, Gwynn &#xa0;L, et al. &#xa0;COVID-19 mRNA vaccination reduces the occurrence of post-COVID conditions in U.S. children aged 5&#x2013;17 years following Omicron SARS-CoV-2 infection, July 2021-September 2022. Open Forum Infect Dis &#xa0;2023; 10:XXX&#x2013;XX.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10878356</ArticleId><ArticleId IdType="pubmed">38379567</ArticleId></ArticleIdList></Reference><Reference><Citation>Razzaghi &#xa0;H, Forrest &#xa0;CB, Hirabayashi &#xa0;K, et al. &#xa0;Vaccine effectiveness against long COVID in children. Pediatrics &#xa0;2024; 153:e2023064446.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10979300</ArticleId><ArticleId IdType="pubmed">38225804</ArticleId></ArticleIdList></Reference><Reference><Citation>Catal&#xe0; &#xa0;M, Mercad&#xe9;-Besora &#xa0;N, Kolde &#xa0;R, et al. &#xa0;The effectiveness of COVID-19 vaccines to prevent long COVID symptoms: staggered cohort study of data from the UK, Spain, and Estonia. Lancet Respir Med &#xa0;2024; 12:225&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">38219763</ArticleId></ArticleIdList></Reference><Reference><Citation>Lundberg-Morris &#xa0;L, Leach &#xa0;S, Xu &#xa0;Y, et al. &#xa0;COVID-19 vaccine effectiveness against post-COVID-19 condition among 589 722 individuals in Sweden: population based cohort study. BMJ &#xa0;2023; 383:e076990.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10666099</ArticleId><ArticleId IdType="pubmed">37993131</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwan &#xa0;AC, Ebinger &#xa0;JE, Botting &#xa0;P, Navarrette &#xa0;J, Claggett &#xa0;B, Cheng &#xa0;S. Association of COVID-19 vaccination with risk for incident diabetes after COVID-19 infection. JAMA Netw Open &#xa0;2023; 6:e2255965.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9929690</ArticleId><ArticleId IdType="pubmed">36787145</ArticleId></ArticleIdList></Reference><Reference><Citation>Nehme &#xa0;M, Vetter &#xa0;P, Chappuis &#xa0;F, et al. &#xa0;Prevalence of post-coronavirus disease condition 12 weeks after Omicron infection compared with negative controls and association with vaccination status. Clin Infect Dis &#xa0;2022; 76:1567&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">36519381</ArticleId></ArticleIdList></Reference><Reference><Citation>Cezard &#xa0;GI, Denholm &#xa0;RE, Knight &#xa0;R, et al. &#xa0;Impact of vaccination on the association of COVID-19 with cardiovascular diseases: an OpenSAFELY cohort study. Nat Commun &#xa0;2024; 15:2173.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10928172</ArticleId><ArticleId IdType="pubmed">38467603</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie &#xa0;Z, Stallings-Smith &#xa0;S, Patel &#xa0;S, Case &#xa0;S, Hong &#xa0;Y-R. COVID-19 booster vaccine uptake and reduced risks for long-COVID: a cross-sectional study of a U.S. adult population. Vaccine &#xa0;2024; 42:3529&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">38670844</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozonoff &#xa0;A, Jayavelu &#xa0;ND, Liu &#xa0;S, et al. &#xa0;Features of acute COVID-19 associated with post-acute sequelae of SARS-CoV-2 phenotypes: results from the IMPACC study. Nat Commun &#xa0;2024; 15:216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10764789</ArticleId><ArticleId IdType="pubmed">38172101</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang &#xa0;H, Wei &#xa0;Y, Hung &#xa0;CT, et al. &#xa0;Association of nirmatrelvir-ritonavir with post-acute sequelae and mortality in patients admitted to hospital with COVID-19: a retrospective cohort study. Lancet Infect Dis. &#xa0;In press.</Citation><ArticleIdList><ArticleId IdType="pubmed">38710190</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu &#xa0;J, Han &#xa0;Z-H, Wang &#xa0;C-Q, Zhang &#xa0;J-F. The impacts of nirmatrelvir&#x2013;ritonavir on myocardial injury and long-term cardiovascular outcomes in hospitalized patients with COVID-19 amid the Omicron wave of the pandemic. Cardiovasc Drugs Ther. &#xa0;In press.</Citation><ArticleIdList><ArticleId IdType="pubmed">38466547</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang &#xa0;W, Wang &#xa0;Y-H, Huang &#xa0;C-H, Hsieh &#xa0;T-H, Ibarburu &#xa0;GH, Wei &#xa0;JC-C. Paxlovid use is associated with lower risk of cardiovascular diseases in COVID-19 patients with autoimmune rheumatic diseases: a retrospective cohort study. BMC Med &#xa0;2024; 22:117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10938827</ArticleId><ArticleId IdType="pubmed">38481216</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffin &#xa0;D, McNeil &#xa0;C, Okusa &#xa0;J, et al. &#xa0;Does monoclonal antibody treatment for COVID-19 impact short and long-term outcomes in a large generalisable population? A retrospective cohort study in the USA. BMJ Open &#xa0;2023; 13:e069247.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10414114</ArticleId><ArticleId IdType="pubmed">37553188</ArticleId></ArticleIdList></Reference><Reference><Citation>Gebo &#xa0;KA, Heath &#xa0;SL, Fukuta &#xa0;Y, et al. &#xa0;Early antibody treatment, inflammation, and risk of post-COVID conditions. mBio &#xa0;2023; 14:e0061823.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10653913</ArticleId><ArticleId IdType="pubmed">37724870</ArticleId></ArticleIdList></Reference><Reference><Citation>Bramante &#xa0;CT, Buse &#xa0;JB, Liebovitz &#xa0;DM, et al. &#xa0;Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial. Lancet Infect Dis &#xa0;2023; 23:1119&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11259948</ArticleId><ArticleId IdType="pubmed">37302406</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie &#xa0;Y, Choi &#xa0;T, Al-Aly &#xa0;Z. Molnupiravir and risk of post-acute sequelae of COVID-19: cohort study. BMJ &#xa0;2023; 381:e074572.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10126525</ArticleId><ArticleId IdType="pubmed">37161995</ArticleId></ArticleIdList></Reference><Reference><Citation>Ioannou &#xa0;GN, Berry &#xa0;K, Rajeevan &#xa0;N, et al. &#xa0;Effectiveness of nirmatrelvir&#x2013;ritonavir against the development of post&#x2013;COVID-19 conditions among U.S. veterans. Ann Intern Med &#xa0;2023; 176:1486&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10620954</ArticleId><ArticleId IdType="pubmed">37903369</ArticleId></ArticleIdList></Reference><Reference><Citation>Cha-Silva &#xa0;AS, Gavaghan &#xa0;MB, Bergroth &#xa0;T, et al. &#xa0;Effectiveness of nirmatrelvir-ritonavir for the prevention of COVID-19&#x2013;related hospitalization and mortality: a systematic literature review. Am J Ther &#xa0;2024; 31:e246&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11060058</ArticleId><ArticleId IdType="pubmed">38691664</ArticleId></ArticleIdList></Reference><Reference><Citation>Davelaar &#xa0;J, Jessurun &#xa0;N, Schaap &#xa0;G, Bode &#xa0;C, Vonkeman &#xa0;H. The effect of corticosteroids, antibiotics, and anticoagulants on the development of post-COVID-19 syndrome in COVID-19 hospitalized patients 6 months after discharge: a retrospective follow up study. Clin Exp Med &#xa0;2023; 23:4881&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10725368</ArticleId><ArticleId IdType="pubmed">37552413</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramonfaur &#xa0;D, Gasperetti &#xa0;A, Blake &#xa0;VE, et al. &#xa0;The global clinical studies of long COVID. Int J Infect Dis &#xa0;2024; 146:107105.</Citation><ArticleIdList><ArticleId IdType="pubmed">38782355</ArticleId></ArticleIdList></Reference><Reference><Citation>Byambasuren &#xa0;O, Stehlik &#xa0;P, Clark &#xa0;J, Alcorn &#xa0;K, Glasziou &#xa0;P. Effect of COVID-19 vaccination on long COVID: systematic review. BMJ Med &#xa0;2023; 2:e000385.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9978692</ArticleId><ArticleId IdType="pubmed">36936268</ArticleId></ArticleIdList></Reference><Reference><Citation>Strain &#xa0;WD, Sherwood &#xa0;O, Banerjee &#xa0;A, Van der Togt &#xa0;V, Hishmeh &#xa0;L, Rossman &#xa0;J. The impact of COVID vaccination on symptoms of long COVID: an international survey of people with lived experience of long COVID. Vaccines (Basel) &#xa0;2022; 10:652.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9146071</ArticleId><ArticleId IdType="pubmed">35632408</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel &#xa0;NJ, Cook &#xa0;C, Vanni &#xa0;K, et al. &#xa0;Impact of vaccination on postacute sequelae of SARS CoV-2 infection in patients with rheumatic diseases. Ann Rheum Dis &#xa0;2023; 82:565&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10225013</ArticleId><ArticleId IdType="pubmed">36442978</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran &#xa0;V-T, Perrodeau &#xa0;E, Saldanha &#xa0;J, Pane &#xa0;I, Ravaud &#xa0;P. Efficacy of first dose of COVID-19 vaccine versus no vaccination on symptoms of patients with long COVID: target trial emulation based on ComPaRe e-cohort. BMJ Medicine &#xa0;2023; 2:e000229.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9978748</ArticleId><ArticleId IdType="pubmed">36910458</ArticleId></ArticleIdList></Reference><Reference><Citation>Nayyerabadi &#xa0;M, Fourcade &#xa0;L, Joshi &#xa0;SA, et al. &#xa0;Vaccination after developing long COVID: impact on clinical presentation, viral persistence, and immune responses. Int J Infect Dis &#xa0;2023; 136:136&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">37717649</ArticleId></ArticleIdList></Reference><Reference><Citation>Pena-Orbea &#xa0;C, Lapin &#xa0;B, Li &#xa0;Y, et al. &#xa0;Sleep disturbance severity and correlates in post-acute sequelae of COVID-19 (PASC). J Gen Intern Med &#xa0;2023; 38:2015&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10072019</ArticleId><ArticleId IdType="pubmed">37014604</ArticleId></ArticleIdList></Reference><Reference><Citation>Faridzadeh &#xa0;A, Tabashiri &#xa0;A, Miri &#xa0;HH, Mahmoudi &#xa0;M. The role of melatonin as an adjuvant in the treatment of COVID-19: a systematic review. Heliyon &#xa0;2022; 8:e10906.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9540685</ArticleId><ArticleId IdType="pubmed">36254292</ArticleId></ArticleIdList></Reference><Reference><Citation>Galperine &#xa0;T, Choi &#xa0;Y, Pagani &#xa0;J-L, et al. &#xa0;Temporal changes in fecal microbiota of patients infected with COVID-19: a longitudinal cohort. BMC Infect Dis &#xa0;2023; 23:537.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10436399</ArticleId><ArticleId IdType="pubmed">37596518</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang &#xa0;L, Xu &#xa0;Z, Mak &#xa0;JWY, et al. &#xa0;Gut microbiota-derived synbiotic formula (SIM01) as a novel adjuvant therapy for COVID-19: an open-label pilot study. J Gastroenterol Hepatol &#xa0;2022; 37:823&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9115073</ArticleId><ArticleId IdType="pubmed">35170078</ArticleId></ArticleIdList></Reference><Reference><Citation>Lau &#xa0;RI, Su &#xa0;Q, Lau &#xa0;ISF, et al. &#xa0;A synbiotic preparation (SIM01) for post-acute COVID-19 syndrome in Hong Kong (RECOVERY): a randomised, double-blind, placebo-controlled trial. Lancet Infect Dis &#xa0;2024; 24:256&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">38071990</ArticleId></ArticleIdList></Reference><Reference><Citation>Parker &#xa0;M, Sawant &#xa0;HB, Flannery &#xa0;T, et al. &#xa0;Effect of using a structured pacing protocol on post-exertional symptom exacerbation and health status in a longitudinal cohort with the post-COVID-19 syndrome. J Med Virol &#xa0;2023; 95:e28373.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9878088</ArticleId><ArticleId IdType="pubmed">36461167</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghali &#xa0;A, Lacombe &#xa0;V, Ravaiau &#xa0;C, et al. &#xa0;The relevance of pacing strategies in managing symptoms of post-COVID-19 syndrome. J Transl Med &#xa0;2023; 21:375.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10248991</ArticleId><ArticleId IdType="pubmed">37291581</ArticleId></ArticleIdList></Reference><Reference><Citation>Spiesshoefer &#xa0;J, Regmi &#xa0;B, Senol &#xa0;M, et al. &#xa0;Potential diaphragm muscle weakness-related dyspnea persists two years after COVID-19 and could be improved by inspiratory muscle training: results of an observational and an interventional trial. Am J Respir Crit Care Med. &#xa0;2024; May 19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11389583</ArticleId><ArticleId IdType="pubmed">38763165</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith &#xa0;A, Greenwood &#xa0;D, Horton &#xa0;M, et al. &#xa0;Psychometric analysis of the modified COVID-19 yorkshire rehabilitation scale (C19-YRSm) in a prospective multicentre study. BMJ Open Respir Res &#xa0;2024; 11:e002271.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11086182</ArticleId><ArticleId IdType="pubmed">38724221</ArticleId></ArticleIdList></Reference><Reference><Citation>da Silva &#xa0;ALG, Vieira &#xa0;LDP, Dias &#xa0;LS, et al. &#xa0;Impact of long COVID on the heart rate variability at rest and during deep breathing maneuver. Sci Rep &#xa0;2023; 13:22695.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10733257</ArticleId><ArticleId IdType="pubmed">38123689</ArticleId></ArticleIdList></Reference><Reference><Citation>Kai &#xa0;S, Nagino &#xa0;K, Aoki &#xa0;T, et al. &#xa0;Cardiac autonomic nervous system activity during slow breathing in supine position. Rehabil Res Pract &#xa0;2021; 2021:6619571.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7936890</ArticleId><ArticleId IdType="pubmed">33728068</ArticleId></ArticleIdList></Reference><Reference><Citation>Mauro &#xa0;M, Luca &#xa0;C, Nicoletta &#xa0;B, Elisa &#xa0;Z, Francesca &#xa0;LF. Heart rate variability modulation through slow paced breathing in healthcare workers with long-COVID: a case-control study. Am J Med. &#xa0;2024; May 23.</Citation><ArticleIdList><ArticleId IdType="pubmed">38795941</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuut &#xa0;TA, M&#xfc;ller &#xa0;F, Csorba &#xa0;I, et al. &#xa0;Efficacy of cognitive-behavioral therapy targeting severe fatigue following coronavirus disease 2019: results of a randomized controlled trial. Clin Infect Dis &#xa0;2023; 77:687&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10495128</ArticleId><ArticleId IdType="pubmed">37155736</ArticleId></ArticleIdList></Reference><Reference><Citation>Vink &#xa0;M, Vink-Niese &#xa0;A. The updated NICE guidance exposed the serious flaws in CBT and graded exercise therapy trials for ME/CFS. Healthcare (Basel) &#xa0;2022; 10:898.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9141828</ArticleId><ArticleId IdType="pubmed">35628033</ArticleId></ArticleIdList></Reference><Reference><Citation>Geraghty &#xa0;K, Jason &#xa0;L, Sunnquist &#xa0;M, Tuller &#xa0;D, Blease &#xa0;C, Adeniji &#xa0;C. The &#x2018;cognitive behavioural model&#x2019; of chronic fatigue syndrome: critique of a flawed model. Health Psychol Open &#xa0;2019; 6:2055102919838907.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6482658</ArticleId><ArticleId IdType="pubmed">31041108</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson &#xa0;JS, Thornton &#xa0;AC, Ainger &#xa0;T, Garvy &#xa0;BA. Long-term high-dose immunoglobulin successfully treats long COVID patients with pulmonary, neurologic, and cardiologic symptoms. Front Immunol &#xa0;2023; 13:1033651.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9932260</ArticleId><ArticleId IdType="pubmed">36818469</ArticleId></ArticleIdList></Reference><Reference><Citation>Fesharaki-Zadeh &#xa0;A, Lowe &#xa0;N, Arnsten &#xa0;AFT. Clinical experience with the &#x3b1;2A-adrenoceptor agonist, guanfacine, and N-acetylcysteine for the treatment of cognitive deficits in &#x201c;long-COVID19.&#x201d; &#xa0;Neuroimmunol Rep &#xa0;2023; 3:100154.</Citation></Reference><Reference><Citation>Momtazmanesh &#xa0;S, Ansari &#xa0;S, Izadi &#xa0;Z, et al. &#xa0;Effect of famotidine on cognitive and behavioral dysfunctions induced in post-COVID-19 infection: a randomized, double-blind, and placebo-controlled study. J Psychosom Res &#xa0;2023; 172:111389.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10229204</ArticleId><ArticleId IdType="pubmed">37327698</ArticleId></ArticleIdList></Reference><Reference><Citation>Glynne &#xa0;P, Tahmasebi &#xa0;N, Gant &#xa0;V, Gupta &#xa0;R. Long-COVID following mild SARS CoV-2 infection: characteristic T cell alterations and response to antihistamines. J Investig Med &#xa0;2022; 70:61&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8494538</ArticleId><ArticleId IdType="pubmed">34611034</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto &#xa0;MD, Lambert &#xa0;N, Downs &#xa0;CA, et al. &#xa0;Antihistamines for postacute sequelae of SARS-CoV-2 infection. J Nurse Pract &#xa0;2022; 18:335&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8820139</ArticleId><ArticleId IdType="pubmed">35153633</ArticleId></ArticleIdList></Reference><Reference><Citation>Mashauri &#xa0;HL. COVID-19 histamine theory: why antihistamines should be incorporated as the basic component in COVID-19 management? &#xa0;Health Sci Rep &#xa0;2023; 6:e1109.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9903129</ArticleId><ArticleId IdType="pubmed">36778771</ArticleId></ArticleIdList></Reference><Reference><Citation>Hurt &#xa0;RT, Yadav &#xa0;S, Schroeder &#xa0;DR, et al. &#xa0;Longitudinal progression of patients with long COVID treated in a post-COVID clinic: a cross-sectional survey. J Prim Care Community Health &#xa0;2024; 15:21501319241258671.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11141226</ArticleId><ArticleId IdType="pubmed">38813984</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang &#xa0;JY, Pao &#xa0;J-B, Lee &#xa0;C-H, Wang &#xa0;J-Y, Lee &#xa0;M-C, Wu &#xa0;T-T. Corticosteroids for COVID-19-induced olfactory dysfunction: a comprehensive systematic review and meta-analysis of randomized controlled trials. PLoS One &#xa0;2023; 18:e0289172.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10734960</ArticleId><ArticleId IdType="pubmed">38127940</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadanny &#xa0;A, Zilberman-Itskovich &#xa0;S, Catalogna &#xa0;M, et al. &#xa0;Long term outcomes of hyperbaric oxygen therapy in post COVID condition: longitudinal follow-up of a randomized controlled trial. Sci Rep &#xa0;2024; 14:3604.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10869702</ArticleId><ArticleId IdType="pubmed">38360929</ArticleId></ArticleIdList></Reference><Reference><Citation>Zilberman-Itskovich &#xa0;S, Catalogna &#xa0;M, Sasson &#xa0;E, et al. &#xa0;Hyperbaric oxygen therapy improves neurocognitive functions and symptoms of post-COVID condition: randomized controlled trial. Sci Rep &#xa0;2022; 12:11252.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9276805</ArticleId><ArticleId IdType="pubmed">35821512</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews &#xa0;JS, Boonyaratanakornkit &#xa0;JB, Krusinska &#xa0;E, Allen &#xa0;S, Posada &#xa0;JA. Assessment of the impact of RNase in patients with severe fatigue related to post-acute sequelae of SARS-CoV-2 infection (PASC): a randomized phase 2 trial of RSLV-132. Clin Infect Dis. &#xa0;2024; May 10.</Citation><ArticleIdList><ArticleId IdType="pubmed">38728385</ArticleId></ArticleIdList></Reference><Reference><Citation>Connor &#xa0;C, Taylor &#xa0;HA. The importance of including long COVID outcomes when developing novel treatments for acute COVID-19. J Infect Dis. &#xa0;In press; May 20.</Citation><ArticleIdList><ArticleId IdType="pubmed">38768246</ArticleId></ArticleIdList></Reference><Reference><Citation>Robineau &#xa0;O, Zins &#xa0;M, Touvier &#xa0;M, et al. &#xa0;Long-lasting symptoms after an acute COVID-19 infection and factors associated with their resolution. JAMA Netw Open &#xa0;2022; 5:e2240985.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9647489</ArticleId><ArticleId IdType="pubmed">36350653</ArticleId></ArticleIdList></Reference><Reference><Citation>Samarasekera &#xa0;U. Peter Hotez: physician-scientist-warrior combating anti-science. Lancet &#xa0;2024; 403:134.</Citation><ArticleIdList><ArticleId IdType="pubmed">38218605</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>